Germany's Gerresheimer prelim Q3 revenue rises on strong demand for drug delivery devices
Germany's Gerresheimer prelim Q3 revenue rises on strong demand for drug delivery devices
Overview
Germany pharma packaging provider's preliminary Q3 revenue rose 8% yr/yr to EUR 605 mln
Adjusted EBITDA for Q3 remained stable compared to prior year
Revenue growth driven by higher demand for drug delivery devices
Outlook
Gerresheimer expects a stronger Q4 2026 with further earnings improvement, in line with guidance
Company expects completion of Primary Packaging Plastics business sale in Q1 2027
Measures underway to improve capacity utilization and competitiveness in Tubular Glass business
Result Drivers
DRUG DELIVERY DEVICES - Co said rising demand for drug delivery devices drove revenue growth in Containment & Delivery Systems division
INVENTORY REDUCTION - Co said inventory reductions in Moulded Glass division lowered capacity utilization and negatively impacted adjusted EBITDA
DIVISION PERFORMANCE - Co said weaker performance in Tubular Glass Europe and Moulded Glass divisions contributed to lower adjusted EBITDA for 9M period
Company press release: ID:nEQ7M0XGpa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue |
| EUR 605 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 9 "hold" and 3 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Gerresheimer AG is €26.90, about 15.7% below its October 29 closing price of €31.90
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 9 three months ago
Reuters Recommended Reads
Oct 29 - Germany's Wacker Chemie's Q3 core profit nearly doubles on cost cuts; keeps outlook
Oct 29 - US drugmaker Eli Lilly beats Q3 revenue estimates on product demand, lifts FY outlook
Oct 29 - Merck Q3 profit beats on Keytruda demand
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Gerresheimer AG
See all newsGermany's Gerresheimer prelim Q3 revenue rises on strong demand for drug delivery devices
Brief: Gerresheimer Reports Q3 Revenue Of EUR 605 Mln
Brief: Gerresheimer Completes Sale Of Centor
Brief: Gerresheimer Targets Leverage At Or Below 3x Net Debt To Ebitda
Gerresheimer gains as Q2 shows quarter-on-quarter recovery